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Purpose: Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) 
are major mediators of angiogenesis and are induced by tissue inflammation and 
hypoxia. The purpose of this study was to investigate whether serum VEGF and 
Ang-2 are associated with the presence of hemoptysis and the extent of systemic 
inflammation in patients with inflammatory lung diseases. Materials and Meth-
ods: We prospectively enrolled 52 patients with inflammatory lung disease be-
tween June 2008 and October 2009. Results: The median values of VEGF and 
Ang-2 were 436 pg/mL and 2383 pg/mL, respectively. There was a significant 
positive correlation between serum Ang-2 and VEGF levels. VEGF levels were 
not significantly different according to the presence of hemoptysis. C-reactive pro-
tein (CRP) and Ang-2 level were significantly higher in patients without hemopty-
sis (n=26) than in those with hemoptysis (n=26; p<0.001 and p<0.001, respective-
ly). CRP and arterial oxygen tension (PaO2) were significantly correlated with both 
serum VEGF (p=0.032 and p=0.016, respectively) and Ang-2 levels (p<0.001 and 
p=0.041, respectively), after adjusting for other factors. Age and the absence of he-
moptysis were factors correlated with serum Ang-2 levels. Conclusion: Our study 
suggests that serum VEGF and Ang-2 levels are associated with PaO2 and the se-
verity of inflammation rather than the presence of hemoptysis in patients with in-
flammatory lung diseases. Thus, hemoptysis may not be mediated by increased se-
rum levels of VEGF and Ang-2 in patients with inflammatory lung diseases, and 
further studies are required to determine the mechanisms of hemoptysis.
Key Words:    Angiogenesis, angiopoietin-2, hemoptysis, inflammation, vascular 
endothelial growth factor
INTRODUCTION
Angiogenesis is characterized by the formation of new microvessels from preex-Hye Yun Park, et al.
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Patients with hemoptysis (hemoptysis group) were enrolled 
if they had hemoptysis within 2 weeks before study enroll-
ment, and the patients without hemoptysis (no hemoptysis 
group) were enrolled if they did not have any hemoptysis 
more than 2 years before study enrollment. All study pa-
tients except one were admitted to general ward or emer-
gency department for the management of symptomatic be-
nign lung diseases. We excluded patients with neoplastic 
conditions, including lung cancer, vasculitis, and lung dis-
ease associated with collagen vascular disease. Serum sam-
ples for VEGF and Ang-2, clinical data, such as age, gen-
der, smoking status, clinical symptoms, and laboratory data, 
including peripheral white blood cell (WBC) count, hemo-
globin (Hb), prothrombin time (PT), C-reactive protein 
(CRP), and arterial oxygen tension (PaO2), were obtained at 
study enrollment.
Determination of sample size
The required sample size was calculated based on VEGF 
levels according to the presence of hemoptysis in patients 
with asperilloma.6 Assuming 437±164 pg/mL of VEGF in 
the hemoptysis group and 162±102 pg/mL in the no he-
moptysis group, a sample size of 42 patients (21 per group) 
was required to detect a 120 pg/mL difference between the 
two groups with a power of 90% and α error of 0.05 using a 
two-tailed test.17 Anticipating a potential 20% drop-out rate, 
we planned to include 52 subjects (26 per group).
Measurement of VEGF and Ang-2
Serum samples from each individual were obtained at the 
time of study enrollment. Sera were stored at -80°C. Serum 
VEGF and Ang-2 concentrations were measured in tripli-
cate for each sample using a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (R&D Systems, Minne-
apolis, MN, USA). The detection ranges of ELISA kits for 
VEGF and Ang-2 were 31.2-2000 pg/mL and 46.9-3000 
pg/mL, respectively. Therefore, serum was diluted to mea-
sure serum Ang-2 levels.
Statistical analysis
Data presented are expressed as either the median and in-
terquartile range (IQR, 25th and 75th percentiles) or the 
number (percentage) of patients. For univariate analysis or 
relation with hemoptysis, categorical variables were ana-
lyzed using a Pearson χ2 test or Fisher’s exact test; continu-
ous variables were analyzed using a Mann-Whitney U test. 
VEGF and Ang-2 levels did not fit normality assumptions; 
isting vasculature and is associated with numerous inflam-
matory conditions, such as atherosclerosis, arthritis, reti-
nopathy, and tumor growth.1 Previous studies provided 
evidence that inflammation exists in a mutually dependent 
association with angiogenesis.2,3
Among the numerous angiogenic factors, vascular endo-
thelial growth factor (VEGF) is the most extensively stud-
ied and is significantly related to the severity of inflamma-
tory lung diseases, such as active tuberculosis, chronic 
bronchitis, pulmonary aspergilloma, and pulmonary disease 
caused by cystic fibrosis.4-7 Overexpression of VEGF is 
also significantly correlated with lung cancer progression 
and metastasis. Antiangiogenic agents have received wide-
spread attention as targets for lung cancer therapy.8,9 Recent 
studies reported that VEGF elevation correlates significant-
ly with the presence of hemoptysis in patients with pulmo-
nary aspergilloma.6 Another major factor involved in angio-
genesis, angiopoietin-2 (Ang-2), is also induced by 
hypoxemia10 and plays an important role in initiating vessel 
sprouting in concert with VEGF.11,12 In contrast with angio-
poietin-1, which stabilizes blood vessels, Ang-2 destabiliz-
es blood vessels, initiating angiogenic changes instead of 
regression, and promotes the neovascularization of tumor 
cells.13-16
The purpose of this study was to investigate whether se-
rum VEGF and Ang-2 were associated with the presence of 
hemoptysis and the level of systemic inflammation in pa-
tients with inflammatory lung diseases.
MATERIALS AND METHODS
　　　
Study population
The study was approved by the Institutional Review Board 
of Samsung Medical Center (a 2600-bed University affiliat-
ed hospital in Seoul, Korea) and was registered with www.
clinicaltrials.gov (NCT01171768). Informed written con-
sent was obtained from all participants. 
Patients presented to the Samsung Medical Center for the 
treatment of benign inflammatory lung diseases, including 
bronchiectasis, aspergilloma, pneumonia, and post-tubercu-
losis destroyed lung, between June 2008 and December 
2009. Diagnosis of post-tuberculosis destroyed lung (inactive 
tuberculosis) was considered when chest computed tomogra-
phy (CT) scan showed the findings compatible with fibrotic 
sequelae of old tuberculosis and all mycobacterial examina-
tions of sputum or bronchial washing fluid were negative. Serum VEGF and Angiopoietin-2 
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Correlation between serum VEGF or angiopoietin-2 
and other parameters
The median VEGF levels were 375 pg/mL in bronchiecta-
sis, 472 pg/mL in aspergilloma, 554 pg/mL in post-tubercu-
losis destroyed lung, and 451 pg/mL in pneumonia. The 
median Ang-2 levels were 2444 pg/mL in bronchiectasis, 
1689 pg/mL in aspergilloma, 3021 pg/mL in post-tubercu-
losis destroyed lung, and 4344 pg/mL in pneumonia.
Serum Ang-2 levels were significantly correlated with se-
rum VEGF levels (p=0.028) (Fig. 1). Serum VEGF levels 
demonstrated a significant positive correlation with WBC 
and a negative correlation with PaO2 levels (Table 3). Age, 
gender, smoking status, presence of hemoptysis, and CRP 
levels showed no significant correlation with VEGF levels 
thus, log-transformed VEGF and Ang-2 (ln VEGF and ln 
Ang-2) values were used in analyses. As the VEGF and 
Ang-2 levels were measured in triplicate from single pa-
tient samples, a mixed model was used to analyze associa-
tions between parameters. Additionally, to take random ef-
fects between subjects into account, we used the ‘random 
statement’ function in PROC MIXED. All p values are two-
sided with p<0.05 considered to indicate statistical signifi-
cance. Statistical analyses were performed using the SAS 
software (ver. 9.1; SAS Institute, Cary, NC, USA).
 
RESULTS
 
Baseline clinical and laboratory features
Characteristics of the enrolled patients are listed in Table 1. 
In this study, 52 study patients underwent extensive evalua-
tions for underlying disease including chest CT scan (n= 
46), bronchoscopy (n=21), and sputum bacterial and myco-
bacterial examinations (n=44). There were 25 men and 27 
women, with a median age of 58 years (range, 47-66). Of 
the 52 patients, 14 patients (27%) had a history of smoking, 
and 22 (42%) had a history of tuberculosis treatment. The 
most common disease in enrolled patients was bronchiecta-
sis (62%); 14% had an aspergilloma, and 14% had post-tu-
berculosis destroyed lung. Median VEGF and Ang-2 levels 
were 436 pg/mL (257-724) and 2383 pg/mL (1807-3209), 
respectively. In total, 5 patients received oxygen therapy 
(1-2 L/min) on arterial blood gas analysis. 
Comparison of clinical laboratory features depending 
on the presence of hemoptysis
In patients with hemoptysis (n=26), bronchiectasis (54%), 
aspergilloma (27%), and post-tuberculosis destroyed lung 
(19%) were observed. In those without hemoptysis (n=26), 
bronchiectasis (69%), post-tuberculosis destroyed lung 
(8%), pneumonia (19%), and pulmonary tuberculosis (4%) 
were observed. Patients with hemoptysis had more signifi-
cant history of tuberculosis treatment compared with those 
without hemoptysis. However, the median CRP and Ang-2 
levels were significantly higher in patients without hemop-
tysis than in those with hemoptysis (CRP; 0.34 vs. 3.29 
mg/dL; p<0.001, and Ang-2; 2017 vs. 2946 pg/mL; 
p<0.001). There was no significant difference in age, gen-
der, smoking history, presenting symptoms, or laboratory 
findings (including WBC, Hb, PT, PaO2, serum VEGF lev-
els) (Table 2).
Table 1. Baseline Characteristics of Enrolled Patients (n=52)
Median (IQR) or No. (%)
Age      58 (47-66)
Sex 
    Female      25 (48%)
    Male      27 (52%)
Smoking status
    Current smoker        2 (4%)
    Ex-smoker      12 (23%)
    Non-smoker      38 (73%)
Comorbidities
    Hypertension        8 (15%)
    Diabetes mellitus        2 (4%)
    Prior therapy for tuberculosis      22 (42%)
Lung Diseases
    Bronchiectasis      32 (62%)
    Aspergilloma        7 (14%) 
    Post-tuberculosis destroyed lung         7 (14%)
    Pneumonia without bronchiectasis        5 (10%)
    Pulmonary tuberculosis        1 (2%)
Presenting symptoms
    Cough      36 (69%)
    Dyspnea      15 (29%)
    Fever        7 (13%)
Laboratory findings
    WBC (#/μL)  8035 (6257-10533)
    Hemoglobin (g/dL)   12.5 (11.3-14.0)
    PT (INR)   1.05 (0.99-1.13)
    CRP (mg/dL)   1.13 (0.24-4.13)
    PaO2 (mm Hg)   81.7 (66.1-90.5)
    VEGF (pg/mL)     436 (257-724)
    Ang-2 (pg/mL)   2383 (1807-3209)
WBC, white blood cell; PT, prothrombin time; CRP, C-reactive protein; 
VEGF, vascular endothelial growth factor; Ang-2, angiopoietin-2; IQR, in-
terquartile range; INR, international normalized ratio; PaO2, arterial oxygen 
tension.Hye Yun Park, et al.
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of hemoptysis were significantly correlated with serum 
Ang-2 levels (Table 4).
DISCUSSION
In the present study, serum VEGF levels did not differ ac-
cording to the presence of hemoptysis. However, we dem-
onstrated that serum VEGF and Ang-2 levels in patients 
with inflammatory lung diseases correlated significantly 
with elevations in serum CRP and reduction of PaO2.
(Table 3). Ang-2 levels showed significantly positive corre-
lations with age, WBC, and CRP levels, while demonstrat-
ing a negative correlation with PaO2 levels (Table 3).
Multivariate analysis using PROC MIXED for repeated 
measures data was performed to identify factors significant-
ly correlated with serum VEGF or Ang-2 levels. CRP lev-
els and PaO2 were found to be significant correlated with 
both serum VEGF (p=0.032 and p=0.016, respectively) and 
Ang-2 levels (p<0.001 and p=0.041, respectively) after ad-
justing for other factors (age, gender, smoking history, and 
the presence of hemoptysis) (Table 4). Age and the absence 
Table 2. Comparison of Clinical Laboratory Features according to the Presence of Hemoptysis 
With hemoptysis (n=26) Without hemoptysis (n=26)  p value
Age      56 (47-65)      60 (48-66) 0.826
Sex  0.405
    Female      11 (42%)      14 (54%)
    Male      15 (58%)      12 (46%)
Smoking status 0.252
    Current smoker        2 (8%)        0
    Ex-smoker        7 (27%)        5 (19%)
    Non-smoker      17 (65%)      21 (81%)
Comorbidities
    Hypertension        6 (23%)        2 (8%) 0.248
    Diabetes mellitus        1 (4%)        1 (4%) 1.000
    Prior therapy for tuberculosis      15 (58%)        7 (27%) 0.025
Lung diseases 0.005
    Bronchiectasis      14 (54%)      18 (69%)
    Aspergilloma        7 (27%)        0
    Post-tuberculosis destroyed lung        5 (19%)        2 (8%)
    Pneumonia        0        5 (19%)
    Pulmonary tuberculosis        0        1 (4%)
Severity of diseases
    No. of involved lobes        2 (1-3)        3 (2-4) 0.390
Presenting Symptoms
    Cough      16 (62%)      20 (77%) 0.229
    Dyspnea        6 (23%)        9 (35%) 0.358
    Fever        2 (8%)        5 (19%) 0.419
Laboratory findings
    WBC (#/μL)  7645 (6353-9695)  8285 (5973-10638) 0.742
    Hemoglobin (g/dL)      13 (11-14)   12.4 (11.8-13.9) 0.615
    Platelet (×10
3/μL)    216 (186-260)    250 (195 - 317) 0.359
    PT (INR)   1.06 (1.01-1.14)   1.04 (0.98-1.12) 0.359
    aPTT (sec)      36 (31-38)      38 (34-41) 0.039
    CRP (mg/dL)   0.34 (0.13-2.09)   3.29 (0.60-7.19) 0.001
    PaO2 (mm Hg)   83.5 (75.1-94.2)   74.7 (64.7-87.6) 0.142
    VEGF*    389 (270-684)    449 (224-776) 0.934
    Ang-2*  2017 (1633-2597)  2946 (2101-4698) <0.001
WBC, white blood cell; PT, prothrombin time; aPTT, activated partial thromboplastin time; CRP, C-reactive protein; VEGF, vascular endothelial growth factor; 
Ang-2, angiopoietin-2; INR, international normalized ratio; PaO2, arterial oxygen tension.
*The analysis used a mixed model, accounting for the random effect between subjects (logarithmic transformed VEGF and Ang-2 values were used).Serum VEGF and Angiopoietin-2 
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sults also demonstrated that VEGF levels were increased in 
inflammatory lung diseases, such as bronchiectasis, asper-
gilloma, post-tuberculosis destroyed lung, and pneumonia, 
when compared with published normal values.20,21 Addi-
tionally, elevated VEGF levels correlated with severity of 
inflammation. Significant change in the serum VEGF levels 
Angiogenesis, the growth of new capillary blood vessels 
from pre-existing vasculature, is an important contributor to 
tissue inflammation and abnormal remodeling in inflamma-
tory diseases. Consistent with previous data that levels of 
VEGF are significantly elevated in inflammatory disorders, 
including lung inflammatory disease,6,7,18,19 our present re-
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Fig. 1. Correlation between serum VEGF and Ang-2 levels. VEGF, vascular endothelial growth factor; Ang-2, angiopoietin-2. p=0.028.
Table 3. Univariate Analysis of Associations between Serum VEGF or Angiopoietin-2 levels and Other Measured Parameters
Variables
Ln [VEGF] Ln [Ang-2]
Coefficient SE p value Coefficient SE p value
Age  -0.003 0.005 0.524  0.013 0.003 <0.001 
Sex (female*)  0.114 0.128 0.375  0.144 0.081   0.077 
Smoking status
† (non-smoker*)  0.116 0.144 0.423  0.092 0.092   0.317
Comorbidities
    Hypertension (No*) -0.159 0.177 0.370 -0.020 0.113   0.862
    Diabetes mellitus (No*) -0.050 0.333 0.880  0.260 0.211   0.220
    Prior therapy for tuberculosis (No*)  0.089 0.130 0.493 -0.154 0.082   0.061
Presenting symptoms
    Cough (No*)  0.247 0.137 0.074  0.196 0.087   0.026
    Dyspnea (No*)  0.355 0.139 0.011   0.286 0.087   0.001 
    Fever (No*) -0.199 0.187 0.288  0.030 0.120   0.801
    Hemoptysis (No*)  0.011 0.128 0.934 -0.420 0.074 <0.001 
    Amount of hemoptysis (cc)   -0.0001   0.0003 0.672     0.0003 0.0002   0.121
Laboratory findings
    WBC (#/μL)     0.00006     0.00002 0.005          0.000064     0.00001 <0.001 
    Hemoglobin (g/dL) 0.016 0.017 0.358 -0.004 0.011   0.745
    PT (INR) 1.085 0.733 0.141     1.0961 0.462   0.019
    CRP (mg/dL) 0.022 0.02 0.160  0.059 0.009 <0.001 
    PaO2 (mm Hg) -0.006 0.003 0.055 -0.004 0.002   0.027 
Ln, natural logarithm; WBC, white blood cell; PT, prothrombin time; CRP, C-reactive protein; VEGF, Vascular endothelial growth factor; Ang-2, angiopoietin-2; 
SE, standard error; PaO2, arterial oxygen tension.
Analysis using a mixed model to account for the random effect between subjects (logarithmic transformed VEGF and Ang-2 values were used).
*Reference category.
†Smoking status: smokers (current smoker or ex-smoker) and non-smoker.
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ting of various cancers.15,28 To our best knowledge, this is the 
first reported study to evaluate Ang-2 levels in inflammato-
ry lung diseases, including bronchiectasis, post-tuberculosis 
destroyed lung, and aspergilloma.
During development of inflammatory tissue, hypoxic 
conditions can promote angiogenesis, leading to induced 
VEGF and Ang-2 production. Expression of Ang-2 was el-
evated in cultured endothelial cells exposed to hypoxia,29-31 
while VEGF mRNA expression was increased.32,33 In the 
present study, PaO2 levels were correlated inversely with 
VEGF and Ang-2 levels; suggesting that angiogenesis me-
diators may be released in response to low PaO2 in patients 
with inflammatory lung diseases.
Significant associations between VEGF and Ang-2 levels 
have been noted in earlier studies in patients with various tu-
mors,28 diabetes mellitus,34 and asthma.35 The present study 
demonstrated that serum VEGF and Ang-2 levels had a sig-
nificant positive correlation in inflammatory lung diseases.
However, in contrast to a previous study,6 our study did 
not find a significant association between the presence of 
hemoptysis and VEGF levels. This lack of an association 
may be explained by differences in the distribution of dis-
ease between the hemoptysis and the no hemoptysis groups. 
As shown in Table 2, the prevalence of bronchiectasis (54%), 
aspergilloma (27%), and post-tuberculosis destroyed lung 
(19%) in the hemoptysis group differed from the no hemop-
tysis group where bronchiectasis (69%), pneumonia (19%), 
and post-tuberculosis destroyed lung (8%) were prevalent. 
with the treatment of inflammatory lung diseases have been 
reported.4,6 To our best knowledge, however, our present 
study is the first to demonstrate that serum VEGF levels are 
positively correlated with serum CRP levels and WBCs. In 
a previous study on patients undergoing major surgery, 
there was no significant correlation between increases in se-
rum VEGF levels and serum IL-6 or CRP levels.22
Recently, several clinical studies have shown that circu-
lating levels of Ang-2 are increased in septic shock patients, 
as well as non-septic patients with, or at risk of, acute lung 
injury/acute respiratory distress syndrome; this is related to 
vascular permeability and pulmonary dysfunction.23-26 In 
these studies, serum Ang-2 levels were positively correlated 
with serum CRP levels. In the present study, Ang-2 levels 
were positively correlated with CRP levels and WBCs, both 
representing markers of inflammation. Compared with the 
levels of Ang-2 in previous studies,23,25,27 the median level 
of Ang-2 in septic shock patients was greater than 4000 pg/
mL; this is significantly higher than the levels seen in the 
current study (median Ang-2 level of 2383 pg/mL). How-
ever, the levels of Ang-2 in the current study are similar to 
data measured in cancer patients, including lung, breast, 
and prostate,15,28 and were greater than the levels of Ang-2 
in the healthy volunteers without lung disease (1000-1500 
pg/mL).28 Our findings suggest that high Ang-2 levels are 
associated with the severity of inflammatory lung disease in 
patients without sepsis, and that the Ang-2 levels in inflam-
matory diseases are similar to the levels reported in the set-
Table 4. Multivariate Correlations between Serum VEGF or Angiopoietin-2 Levels and Other Measured Parameters
Coefficient SE T  p value
Ln [VEGF]
    Age -0.007 0.005 -1.26 0.211
    Sex (female*) -0.142 0.177 -0.80 0.424
    Smoking status
† (non-smoker*) 0.121 0.180 0.67 0.503
    The presence of hemoptysis 0.188 0.152 1.24 0.218
    CRP (mg/dL) 0.042 0.020 2.16 0.032
    PaO2 (mm Hg) -0.007 0.003 -2.45 0.016
Ln [Ang-2]
    Age 0.012 0.003 4.43 <0.001
    Sex (female*) 0.127 0.090 1.42 0.157
    Smoking status
† (non-smoker*) 0.025 0.091 0.28 0.783
    The presence of hemoptysis -0.275 0.077 -3.59 <0.001 
    CRP (mg/dL) 0.038 0.010 3.88 <0.001
    PaO2 (mm Hg) -0.003 0.002 -2.06 0.041
Ln, natural logarithm; T, t statistic value; VEGF, vascular endothelial growth factor; Ang-2, angiopoietin-2; CRP, C-reactive protein; SE, standard error; PaO2, 
arterial oxygen tension.
Analysis using a mixed model to account for the random effect between subjects (logarithmic transformed VEGF and Ang-2 values were used).
*Reference category.
†Smoking status: smokers (current smoker or ex-smoker) and non-smoker.Serum VEGF and Angiopoietin-2 
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When the VEGF levels were compared between patients 
with aspergilloma, which were present only in the hemop-
tysis group, and those with pneumonia, which were present 
only in the non-hemoptysis group, no significant difference 
in VEGF levels was observed. Additionally, when compari-
son was restricted to patients with bronchiectasis from both 
groups, VEGF levels were not significantly correlated with 
the presence of hemoptysis. The lack of a significant differ-
ence in VEGF levels between the hemoptysis and no he-
moptysis groups can be partially explained by the different 
disease distribution in the two groups. In previous reports 
of associations between VEGF levels and hemoptysis in 21 
pulmonary aspergilloma patients,6 the mean serum VEGF 
levels in 6 patients with hemoptysis and 15 patients without 
hemoptysis were 437 pg/mL and 162 pg/mL, respectively. 
The reported serum VEGF levels were similar to the asper-
gilloma patients with hemoptysis in the current study.
The present study has several other limitations. The mea-
surements of VEGF and Ang-2 levels were made with se-
rum, not lung tissue; it is unclear whether serum VEGF or 
Ang-2 levels reflect the levels in lung tissue. Also, because 
the present study was conducted with multiple inflammato-
ry lung diseases, the sample size might have influenced the 
statistical power; this limits the interpretation of the study 
despite the fact that a formal sample size calculation was 
performed. Finally, the timing of measurement of serum 
angiogenesis markers in this study was not uniform in rela-
tion to stages of lung injury. Since the level of serum angio-
genesis markers could vary in different stages of lung inju-
ry, our data should be interpreted conservatively. A larger-
scale study in patients with bronchiectasis, aspergilloma, 
and pneumonia is needed to further clarify the association 
between hemoptysis and VEGF levels.
In conclusion, serum VEGF and Ang-2 levels were asso-
ciated with the PaO2 and the severity of inflammation, rather 
than the presence of hemoptysis in patients with inflamma-
tory lung diseases. Hemoptysis in patients with inflammato-
ry lung diseases may not be mediated by increased serum 
levels of VEGF and Ang-2. Further studies are required to 
determine the mechanism(s) of hemoptysis in patients with 
inflammatory lung disease.
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